hVIVO Chairman Cathal Friel shares his thoughts on £13.6m contract

hVIVO plc (LON:HVO) announced that it has signed a £13.6m contract with a US-based biopharmaceutical client to test its respiratory syncytial virus antiviral candidate, using hVIVO’s established RSV Human Challenge Study Model.

“I am delighted to announce that hVIVO has signed another significant challenge study contract, this time a £13.6m contract with a US based biopharma company. 

We are delighted to see the continuous growing demand for human challenge trials from both new and existing customers. As the team outlined at last week’s Capital Markets Day, as the global pharma and biotech players learn more about the many benefits of human challenge trials, not only are the number of contracts increasing, but the size of these contracts are growing significantly also. As the world leader in human challenge trials, we are delighted to see this growth. 

Chairman Cathal Friel “

The Phase 2a double-blinded placebo-controlled human challenge trial will take place at the Company’s specialist quarantine facilities in Whitechapel and will evaluate the efficacy profile of the antiviral against RSV infection. The study is expected to commence in Q3/Q4 2023, with the revenue being recognised in 2023 and 2024. As part of the study, hVIVO will recruit healthy volunteers via the Company’s dedicated volunteer recruitment arm, FluCamp.

This contract highlights hVIVO’s world leading expertise in its field and its ability to execute sizable contracts as well as the industry’s renewed focus on developing new treatments for RSV. The Company continues to see growing demand for larger challenge studies from both new and existing clients as they seek greater clarity of data and pursue lower frequency endpoints in an effort to further de-risk their programmes ahead of later stage field studies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO enters 2024 with 90% of revenue guidance already contracted

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced an unaudited trading update for the year ended 31 December 2023. Highlights • Full year revenue of £56.0 million,

    hVIVO plc

    A day in the life of a Laboratory Team Leader at hVIVO

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical

    hVIVO plc

    Companies to follow in 2024: hVIVO

    Here we look at 10 companies from a variety of sectors that have performed in 2023, or which may be positioned for a better year ahead. Also look out for our roundups of oil and gas

    hVIVO plc

    FluCamp 2023: Year in Review

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical

    hVIVO plc

    Irish-listed Hvivo signs €7.3m contract with biotechnology firm

    Pharmaceutical services firm Hvivo has signed a £6.3m (€7.3m) contract with a biotechnology client. Irish-founded Hvivo runs drug trials known as challenge studies from its London clinics. The company will test the biotechnology’s client’s antiviral candidate

    hVIVO plc

    hVIVO appoints Nominated Adviser and Joint Broker

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as

    hVIVO plc

    Hvivo signs €7.3m contract to test cold virus treatment

    Hvivo, the pharmaceutical services company formerly known as Open Orphan, has signed a contract worth £6.3 million (€7.3 million) to test a potential treatment for the common cold. The contract, which is with an unnamed biotechnology

    hVIVO plc

    hVIVO plc £6.3m HRV Contract Signed with Biotechnology Client

    hVIVO plc (Euronext / LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using

    hVIVO plc

    hVIVO reels in £16.8M clinical trial deal for RSV drug

    London-based CRO hVIVO has landed a £16.8 million ($21 million) contract from an unnamed drugmaker to conduct a phase 2 trial of its respiratory syncytial virus (RSV) antiviral drug candidate. The company, which hVIVO has only described as a